Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 21, Issue 3

May-June 2024

In this Issue

ASH Image Bank Challenge
Clinical Trials Corner
Diffusion
Feature
Headlines from Washington
Op Ed
President’s Column

ASH Image Bank Challenge

A Young Man With Thrombocytopenia and Leukopenia

Qing Wei, MD, PhD,Chi Young Ok, MD

View Articletitled, A Young Man With Thrombocytopenia and Leukopenia

Clinical Trials Corner

Bispecific Antibodies in Frontline Large B-cell Lymphoma: Can We Do Better Than Pola-R-CHP?

Avyakta Kallam, MD,Alex Herrera, MD

View Articletitled, Bispecific Antibodies in Frontline Large B-cell Lymphoma: Can We Do Better Than Pola-R-CHP?

Diffusion

Turn It Off! Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms

Antonio Rodriguez-Romera, MSc,Bethan Psaila, MD,PhD

View Articletitled, Turn It Off! Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms

Room To Grow: Bosutinib Approved for Newly Diagnosed or Relapsed/Intolerant Pediatric Chronic Myeloid Leukemia

Sara Zarnegar-Lumley, MD, MS,Lauren Pommert, MD, MS

View Articletitled, Room To Grow: Bosutinib Approved for Newly Diagnosed or Relapsed/Intolerant Pediatric Chronic Myeloid Leukemia

BMT-CTN 1506/MORPHO: A New Standard for MRD-directed Post-transplant Maintenance in Acute Myeloid Leukemia

Alexander Perl, MD,Lori Muffly, MD, MS

View Articletitled, BMT-CTN 1506/MORPHO: A New Standard for MRD-directed Post-transplant Maintenance in Acute Myeloid Leukemia

Commercial CAR T-cell Therapy and Secondary Malignancy

Elizabeth L. Courville, MD

View Articletitled, Commercial CAR T-cell Therapy and Secondary Malignancy

Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

Harish Eswaran, MD,Samuel R. Wilson, MD, MSCR

View Articletitled, Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

Sequencing of Therapy Matters in the Era of Autologous Chimeric Antigen Receptor T-cell Therapy

Karan L. Chohan, MD,Loretta J. Nastoupil, MD

View Articletitled, Sequencing of Therapy Matters in the Era of Autologous Chimeric Antigen Receptor T-cell Therapy

Restoring T-cell Cytotoxicity To Correct Familial Hemophagocytic Lymphohistiocytosis

Melinda Biernacki, MD,Kate Markey, MBBS,PhD

View Articletitled, Restoring T-cell Cytotoxicity To Correct Familial Hemophagocytic Lymphohistiocytosis

Feature

Point-Counterpoint
Chimeric Antigen Receptor T-cell Therapy for First Relapse in Multiple Myeloma: A Promising Strategy

Binod Dhakal, MD, MS

View Articletitled, Point-Counterpoint Chimeric Antigen Receptor T-cell Therapy for First Relapse in Multiple Myeloma: A Promising Strategy

Point-Counterpoint
Bispecific Antibodies in Earlier Lines of Therapy for Patients With Multiple Myeloma: A Bright Future for the New Kids on the Block

Yi Lin, MD, PhD

View Articletitled, Point-Counterpoint Bispecific Antibodies in Earlier Lines of Therapy for Patients With Multiple Myeloma: A Bright Future for the New Kids on the Block

How I Made My Classical Hematology Practice More Efficient

Leslie Padrnos, MD,Surbhi Shah, MBBS, MD

View Articletitled, How I Made My Classical Hematology Practice More Efficient

Not So Benign
Immune Thrombocytopenia: New and Emerging Therapies for a Challenging “Benign” Hematologic Disease

Michael Scott, MD

View Articletitled, Not So Benign Immune Thrombocytopenia: New and Emerging Therapies for a Challenging “Benign” Hematologic Disease

Not So Benign
This Is Not Your Father’s Thrombotic Thrombocytopenic Purpura

Spero R. Cataland, MD

View Articletitled, Not So Benign This Is Not Your Father’s Thrombotic Thrombocytopenic Purpura

Headlines from Washington

ASH Committees Visit Capitol Hill in Support of Funding

View Articletitled, ASH Committees Visit Capitol Hill in Support of Funding

Op Ed

Perspective
Procedure Skills in Hematology Training: Lost Cause or Worth Fighting For?

Anand B. Karnad, MD

View Articletitled, Perspective Procedure Skills in Hematology Training: Lost Cause or Worth Fighting For?

President’s Column

Advancing Diversity and Transparency in Hematologic Clinical Trials

Mohandas Narla, DSc

View Articletitled, Advancing Diversity and Transparency in Hematologic Clinical Trials

Cover Image

Cover Image

All Issues

Email alerts

Latest Issue Alert

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read

Sequencing of Therapy Matters in the Era of Autologous Chimeric Antigen Receptor T-cell Therapy

Restoring T-cell Cytotoxicity To Correct Familial Hemophagocytic Lymphohistiocytosis

Not So Benign
This Is Not Your Father’s Thrombotic Thrombocytopenic Purpura

Perspective
Procedure Skills in Hematology Training: Lost Cause or Worth Fighting For?

ASH Committees Visit Capitol Hill in Support of Funding

Table of Contents

ASH Image Bank Challenge

A Young Man With Thrombocytopenia and Leukopenia

Clinical Trials Corner

Bispecific Antibodies in Frontline Large B-cell Lymphoma: Can We Do Better Than Pola-R-CHP?

Diffusion

Turn It Off! Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms

Room To Grow: Bosutinib Approved for Newly Diagnosed or Relapsed/Intolerant Pediatric Chronic Myeloid Leukemia

BMT-CTN 1506/MORPHO: A New Standard for MRD-directed Post-transplant Maintenance in Acute Myeloid Leukemia

Commercial CAR T-cell Therapy and Secondary Malignancy

Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

Sequencing of Therapy Matters in the Era of Autologous Chimeric Antigen Receptor T-cell Therapy

Restoring T-cell Cytotoxicity To Correct Familial Hemophagocytic Lymphohistiocytosis

Feature

Point-Counterpoint
Chimeric Antigen Receptor T-cell Therapy for First Relapse in Multiple Myeloma: A Promising Strategy

Point-Counterpoint
Bispecific Antibodies in Earlier Lines of Therapy for Patients With Multiple Myeloma: A Bright Future for the New Kids on the Block

How I Made My Classical Hematology Practice More Efficient

Not So Benign
Immune Thrombocytopenia: New and Emerging Therapies for a Challenging “Benign” Hematologic Disease

Not So Benign
This Is Not Your Father’s Thrombotic Thrombocytopenic Purpura

Headlines from Washington

ASH Committees Visit Capitol Hill in Support of Funding

Op Ed

Perspective
Procedure Skills in Hematology Training: Lost Cause or Worth Fighting For?

President’s Column

Advancing Diversity and Transparency in Hematologic Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

ASH Image Bank Challenge

Clinical Trials Corner

Diffusion

Feature

Headlines from Washington

Op Ed

President’s Column

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only